Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine
Tenaya Therapeutics, Inc. (TNYA)
Company Research
Source: GlobeNewswire
Funding will Support Ongoing RIDGE™-1 Clinical Trial of TN-401 Gene Therapy for the Potential Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Initial Data from RIDGE-1 Phase 1b Clinical Trial Expected in 2H25 SOUTH SAN FRANCISCO, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that the California Institute for Regenerative Medicine (CIRM), a state of California Agency that funds regenerative medicine, stem cell, and gene therapy research, has awarded Tenaya Therapeutics an $8.0 million CLIN2 grant. Proceeds from the grant will help fund clinical trial costs for Tenaya’s ongoing Phase 1b RIDGE-1 clinical trial of TN-401 gene therapy. TN-401 is being developed for the treatment of arrhythmogenic right
Show less
Read more
Impact Snapshot
Event Time:
TNYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNYA alerts
High impacting Tenaya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNYA
News
- Tenaya Therapeutics (NASDAQ:TNYA) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc..MarketBeat
- Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed [Yahoo! Finance]Yahoo! Finance
- Tenaya Therapeutics (NASDAQ:TNYA) had its price target lowered by analysts at HC Wainwright from $5.00 to $3.00. They now have a "buy" rating on the stock.MarketBeat
- Tenaya Therapeutics (NASDAQ:TNYA) had its price target lowered by analysts at Chardan Capital from $9.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Tenaya Therapeutics Announces Pricing of Public OfferingGlobeNewswire
TNYA
Earnings
- 11/10/25 - Beat
TNYA
Sec Filings
- 12/17/25 - Form SCHEDULE
- 12/12/25 - Form 8-K
- 12/12/25 - Form 424B5
- TNYA's page on the SEC website